XCR1 and neoplasm: In accordance with this, the administration of IFNα-producing iPSC-derived proliferating myeloid cells (pMCs) to mice strongly activated host CD141+XCR1+ DCs, enhancing their CD8+ T cell priming capacity and thus boosting anti-tumor immune responses [120].